Newpath Resources Inc is in the business of acquiring, exploring, and evaluating mineral resource properties in Canada. . Its property include Northshore property, Schreiber Area, and Orefield project.
相关临床试验
33
16 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
5
15.2%
已完成
10
30.3%
尚未招募
11
33.3%
招募中
5
15.2%
撤回
2
6.1%
暂无批准数据
- A cluster-randomized trial across 16 Kenyan primary care clinics found that an LLM-based clinical decision support tool did not significantly reduce 14-day treatment failure (2.2% vs 2.0%; aOR 0.77, 95% CI 0.55–1.08, P=0.13). - The AI intervention significantly improved clinical documentation quality, including appropriate diagnosis (aOR 1.74), comprehensive notes (aOR 1.68), and appropriate treatment plans (aOR 1.71). - No safety concerns were identified, with similar rates of hospitalization and death between groups, and patient satisfaction was identical across arms. - Antibiotic-related costs were lower in the AI-supported group, and the per-patient LLM cost was just US$0.04, suggesting potential operational net savings.
- WHO declared the Ebola disease outbreak caused by Bundibugyo virus in the DRC and Uganda a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, with 1,406 confirmed cases and 438 deaths reported in the DRC alone. - The WHO added the first molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing, enabling rapid and accurate detection through genetic material identification in blood samples. - Unlike Ebola-Zaire strains, there are currently no approved Bundibugyo virus-specific therapeutics or vaccines, making diagnostic tools and supportive care the primary response measures. - Laboratory testing capacity has expanded from 200–400 tests per day to over 2,000 tests per day across 10 laboratories in affected provinces, supported by WHO and Africa CDC.
- The World Health Organization has granted Phase II pre-qualification to Biological E Limited's Novel Oral Polio Vaccine type 2, enabling complete end-to-end manufacturing at a single integrated facility. - This milestone expands beyond the company's June 2024 Phase I qualification and allows for more resilient global vaccine supply for outbreak control efforts. - Biological E has already manufactured and supplied 700 million doses of nOPV2 to the global stockpile, with the vaccine deployed in over a billion doses worldwide. - The enhanced manufacturing capability strengthens global polio outbreak response readiness by providing continuous, flexible vaccine supply for controlling circulating vaccine-derived poliovirus type 2 outbreaks.
- The Global Health Innovative Technology Fund announced a $460,000 investment to develop a prototype mpox detection test capable of distinguishing between viral clades using the Iso-PAS genetic testing method. - The project involves NIPRO Corporation, TBA Co. Ltd, Japan Institute for Health Security, PATH, and Institut National de Recherche Biomédicale to create rapid diagnostics for resource-limited settings. - Over 170,000 mpox cases were confirmed in 141 countries between January 2022 and October 2025, with children under 5 years showing case fatality ratios of 7-9% in the Democratic Republic of Congo. - Current diagnostic systems for identifying mpox clades remain insufficient, creating urgent need for simple, rapid tests to prevent further infection spread in sub-Saharan Africa.
- PharmaJet is developing a suite of proprietary needle-free self-injection pens for subcutaneous delivery of chronic disease treatments and metabolic peptides, currently in early testing phases. - The company's existing Tropis intradermal system has demonstrated superior user acceptance with over 95% caregiver preference and significant reductions in patient-reported pain and soreness compared to traditional needle injections. - Clinical evidence shows needle-free delivery can improve patient compliance rates, with PharmaJet's technology having been used for over 12 million vaccine injections worldwide. - The new pen injectors will incorporate smart e-technology for dose tracking and aim to address needle aversion barriers that impact treatment compliance in chronic disease management.
- Bharat Biotech and GSK announced they will reduce the price of the world's first malaria vaccine RTS,S by more than half to less than $5 per dose by 2028. - The price reduction is enabled by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins as part of technology transfer between companies. - Bharat Biotech has invested over $200 million in new manufacturing facilities and technology transfers to support the production scale-up and cost reduction. - With Gavi's support, 12 endemic African countries will introduce RTS,S through routine immunization programs by the end of 2025, aiming to protect 50 million more children by 2030.
- Microneedle technology is revolutionizing drug delivery by offering a minimally invasive alternative to traditional injection methods, with applications spanning vaccines, biologics, and gene therapies. - The technology shows particular promise for COVID-19 vaccine delivery and cancer vaccine applications, while also advancing diagnostic capabilities through microneedle-based testing platforms. - Regulatory bodies including the FDA and WHO are developing new guidance frameworks for microneedle device classification and quality standards to support the growing field. - Industry leaders are focusing on innovative fabrication techniques and novel materials to enhance therapeutic outcomes, improve patient compliance, and enable personalized medicine approaches.
